← Back to Clinical Trials
Recruiting NCT01212250
Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
Trial Parameters
Condition Cirrhosis
Sponsor Institute of Liver and Biliary Sciences, India
Study Type INTERVENTIONAL
Phase N/A
Enrollment 132
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2010-09-01
Completion 2026-12-31
Interventions
carvedilolPlacebo
Brief Summary
Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD. After randomization they will be followed up for one year.
Eligibility Criteria
Inclusion Criteria: * Patients of cirrhosis aged 18 to 75 years who have no esophageal or gastric varices. Exclusion Criteria: * Any contra-indication to beta-blockers * Any past EVL or sclerotherapy * Any past history of surgery for portal hypertension * Significant cardio or pulmonary co-morbidity * Any malignancy * Refusal to participate in the study